PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility

by Randy Whitney
April 26, 2019
in Medical, Technology
Reading Time: 3 mins read
0

Laboratory will meet CGMP Requirements of FDA; Will be BSL-2 to allow enhanced in-house verification and validation activities

SALT LAKE CITY–(BUSINESS WIRE)– Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today leasing a new and upgraded, CGMP-ready and Biological Safety Level 2 laboratory facility in Salt Lake City, Utah.

Co-Diagnostics CEO Dwight Egan remarked, “The upgraded facility is nearly perfectly appointed with the necessary amenities to immediately commence production operations. This site will help us to reduce our dependence on outside locations to complete robust validations of the Company’s products, and represents the next step in our growth as a world-class developer of molecular diagnostics. Our trained personnel will now have the capacity to manufacture high-quality products that meet the standards of the U.S. Food and Drug Administration, preparing the Company to seek future FDA approvals for sale domestically and export abroad.”

Mr. Egan continued, “This is another important milestone in the development of Co-Diagnostics as an emerging leader in the molecular diagnostics industry. We are bringing disruptive technology to the market that will dramatically improve test accuracy by reducing false positives via our CoPrimers™ technology, and facilitate multiplexing to test for a broad range of disease states in a patient in a single test which will cut costs to healthcare systems. We are excited with the opportunities ahead in the coming years.”

Biocontainment precautions are required for the safe handling of potentially dangerous biological agents in a laboratory environment. Biological Safety Levels (“BSL”) are determined by the Centers for Disease Control (“CDC”) as a way to categorize which specific controls are necessary for the containment of biological agents based on their risk, transmissibility, severity, etc. Containment levels range from the lowest, BSL-1, to BSL-4, with each level requiring increasingly strict precautions. The Company’s BSL-2 lab will allow trained staff members to conduct certain verification and validation activities on human samples in-house rather than sending investigational use test kits to other facilities. From the FDA website, a CGMP-certified facility refers the Current Good Manufacturing Practice regulations enforced by the FDA, and provides systems that assure proper design, monitoring, and control of manufacturing processes and facilities. The new facility will also house the corporate headquarters for the Company.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Tags: Co-DiagnosticsCODXFDAlaboratory
Previous Post

Wealth Generators’ Crypto Mining Generates $1M in Sales

Next Post

MAMMOTH RESOURCES ANNOUNCES CLOSING ON $720,000 PRIVATE PLACEMENT AND COMMENCEMENT OF DIAMOND DRILLING AT ITS TENORIBA GOLD-SILVER PROJECT, CHIHUAHUA, MEXICO

Randy Whitney

Randy is a marketing specialist with experience creating content for sports and real estate in New York City. He has written for Major League Baseball and Cut4 as well as contributed creatively to the growth and development of startups around the country.

Related Posts

Technology

Apple taps TSMC’s latest tech and BYD races into Japan

September 15, 2022
0
Technology

Fortress China: Xi Jinping’s plan for economic independence

September 15, 2022
0
Technology

Patreon: fight for talent makes creator economy more costly

September 15, 2022
0
Technology

Wall Street shudders after seeing US inflation data

September 14, 2022
0
Technology

After the tech sell-off: will growth investors keep the faith?

September 14, 2022
0
Technology

UK university develops device to restore sense of touch to stroke patients

September 14, 2022
0
Next Post

MAMMOTH RESOURCES ANNOUNCES CLOSING ON $720,000 PRIVATE PLACEMENT AND COMMENCEMENT OF DIAMOND DRILLING AT ITS TENORIBA GOLD-SILVER PROJECT, CHIHUAHUA, MEXICO

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.